Krystal Biotech Inc (KRYS)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 4.29 | 5.63 | 8.18 | 8.87 | 13.82 | 18.08 | 83.31 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Receivables turnover | 2.80 | 2.55 | 1.67 | 2.23 | 1.38 | 1.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payables turnover | 22.81 | 18.74 | 18.36 | 18.26 | 23.36 | 21.98 | 20.61 | 20.35 | 19.04 | 11.39 | 5.99 | 5.75 | 4.64 | 6.61 | 20.91 | 10.83 | 6.52 | 4.70 | 5.61 | 11.65 |
| Working capital turnover | 0.46 | 0.40 | 0.28 | 0.19 | 0.10 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover Analysis:
The inventory turnover ratio for Krystal Biotech Inc has been showing a positive trend, indicating that the company is efficiently managing its inventory. The ratio increased from 8.87 in March 2024 to 4.29 in December 2024, suggesting that the company is selling its inventory more quickly.
Receivables Turnover Analysis:
The receivables turnover ratio for Krystal Biotech Inc has also shown improvement over the period analyzed. The ratio increased from 1.67 in June 2024 to 2.80 in December 2024, indicating that the company is collecting its receivables at a faster rate.
Payables Turnover Analysis:
The payables turnover ratio demonstrates how quickly the company is paying its suppliers. Krystal Biotech Inc's payables turnover ratio fluctuated throughout the period, ranging from 4.64 in December 2021 to 22.81 in December 2024. The increasing ratio suggests that the company is taking longer to pay its suppliers, which could potentially indicate a strain on its cash flow.
Working Capital Turnover Analysis:
The working capital turnover ratio measures how efficiently a company is utilizing its working capital to generate revenue. Krystal Biotech Inc's working capital turnover ratio has been increasing steadily from 0.01 in June 2023 to 0.46 in December 2024. This indicates that the company is effectively utilizing its working capital to generate sales.
Overall, the analysis of Krystal Biotech Inc's activity ratios suggests that the company is effectively managing its inventory, receivables, and working capital. However, the fluctuating payables turnover ratio may require further investigation to understand its impact on the company's financial health and liquidity.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 85.11 | 64.84 | 44.64 | 41.17 | 26.41 | 20.19 | 4.38 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Days of sales outstanding (DSO) | days | 130.27 | 143.32 | 218.43 | 163.38 | 263.86 | 310.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | 16.00 | 19.47 | 19.89 | 19.99 | 15.62 | 16.60 | 17.71 | 17.94 | 19.17 | 32.05 | 60.98 | 63.51 | 78.72 | 55.22 | 17.45 | 33.70 | 55.96 | 77.69 | 65.05 | 31.33 |
Krystal Biotech Inc's activity ratios indicate trends in how efficiently the company manages its inventory, collects receivables, and pays its suppliers.
1. Days of Inventory on Hand (DOH):
- The days of inventory on hand increased steadily from 4.38 days as of June 30, 2023, to 85.11 days as of December 31, 2024. This sharp increase indicates that Krystal Biotech Inc is holding more inventory for a longer period, which may tie up its cash and indicate potential inefficiencies in inventory management.
2. Days of Sales Outstanding (DSO):
- The days of sales outstanding fluctuated over the period but decreased overall from 310.65 days as of September 30, 2023, to 130.27 days by December 31, 2024. This downward trend suggests that the company improved its collections process, reducing the average time taken to collect payments from customers.
3. Number of Days of Payables:
- The number of days of payables decreased gradually from 31.33 days as of March 31, 2020, to 16.00 days by December 31, 2024. This decline indicates that Krystal Biotech Inc has been paying its suppliers more quickly, which may be beneficial in maintaining good relationships with vendors.
Overall, while the days of inventory on hand have increased significantly, the reduction in days of sales outstanding and the timely payment of payables suggest improvements in efficiency and liquidity management by Krystal Biotech Inc.
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | 1.89 | 1.58 | 1.09 | 0.65 | 0.36 | 0.07 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Total asset turnover | 0.28 | 0.25 | 0.19 | 0.12 | 0.07 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
The long-term activity ratios of Krystal Biotech Inc can provide insights into the efficiency of the company in managing its assets over the long run:
1. Fixed Asset Turnover: This ratio measures how efficiently the company is generating sales from its fixed assets. From March 2024 to December 2024, the fixed asset turnover ratio improved significantly, from 0.65 to 1.89. This indicates that Krystal Biotech Inc has been able to utilize its fixed assets more effectively to generate revenue during this period.
2. Total Asset Turnover: The total asset turnover ratio reflects the company's ability to generate sales from all its assets. From March 2024 to December 2024, the total asset turnover ratio increased steadily from 0.12 to 0.28. This improvement suggests that Krystal Biotech Inc has been more efficient in utilizing its total assets to generate revenue over this period.
Overall, the increasing trend in both fixed asset turnover and total asset turnover ratios indicates that Krystal Biotech Inc has been improving its efficiency in utilizing its assets to drive revenue growth, which is a positive sign for the company's long-term financial performance.